

## Hallucinations in Older Adults: A Practical Review

Johanna C. Badcock<sup>\*,1,2</sup>, Frank Larøi<sup>3-5</sup>, Karina Kamp<sup>6</sup>, India Kelsall-Foreman<sup>1</sup>, Romola S. Bucks<sup>1</sup>, Michael Weinborn<sup>1</sup>, Marieke Begemann<sup>8</sup>, John-Paul Taylor<sup>9</sup>, Daniel Collerton<sup>9</sup>, John T. O'Brien<sup>10,oo</sup>, Mohamad El Haj<sup>11</sup>, Dominic ffytch<sup>12</sup>, and Iris E Sommer<sup>7</sup>

<sup>1</sup>School of Psychological Science, University of Western Australia, Perth 6009, Australia; <sup>2</sup>Perth Voices Clinic, Murdoch 6150, Australia; <sup>3</sup>Department of Biological and Medical Psychology, University of Bergen, Bergen, Norway; <sup>4</sup>Psychology and Neuroscience of Cognition Research Unit, University of Liege, Liege, Belgium; <sup>5</sup>Norwegian Centre of Excellence for Mental Disorders Research, University of Oslo, Oslo, Norway; <sup>6</sup>Department of Psychology and Behavioural Science, Aarhus University, Aarhus C, DK 8000, Denmark; <sup>7</sup>Rijks Universiteit Groningen (RUG), Department of Biomedical Sciences of Cells and Systems, University Medical Center Groningen, The Netherlands; <sup>8</sup>Department of Biomedical Sciences of Cells and Systems, University Medical Center, Rijks Universiteit Groningen (RUG), Groningen, The Netherlands; <sup>9</sup>Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, NE4 5PL, UK; <sup>10</sup>Department of Psychiatry, University of Cambridge, Cambridge, UK; <sup>11</sup>Laboratoire de Psychologie des Pays de la Loire (LPPL-EA 4638), Nantes Université, Univ Angers, F-44000 Nantes, France; <sup>12</sup>Department of Old Age Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College, London, UK

\*To whom correspondence should be addressed; School of Psychological Science, The University of Western Australia, 35 Stirling Highway, Perth, 6009; tel: 0423123665, fax: 61864881006, e-mail: [johanna.badcock@uwa.edu.au](mailto:johanna.badcock@uwa.edu.au)

**Older adults experience hallucinations in a variety of social, physical, and mental health contexts. Not everyone is open about these experiences, as hallucinations are surrounded with stigma. Hence, hallucinatory experiences in older individuals are often under-recognized. They are also commonly misunderstood by service providers, suggesting that there is significant scope for improvement in the training and practice of professionals working with this age group. The aim of the present article is to increase knowledge about hallucinations in older adults and provide a practical resource for the health and aged-care workforce. Specifically, we provide a concise narrative review and critique of (1) workforce competency and training issues, (2) assessment tools, and (3) current treatments and management guidelines. We conclude with a brief summary including suggestions for service and training providers and future research.**

*Key words:* hallucinations/assessment/treatment/older adults/training/aged-care

### General Introduction

By 2050, it is estimated that 16% of people will be aged above 65 years, compared with 9% in 2019.<sup>1</sup> Population aging is driving increased attention to the physical and mental health needs of older adults. Here, our focus is on hallucinations—given the wide range of health and aged-care service providers who encounter people with

these experiences in their workplace. Hallucinations can be defined as “a perception-like experience with the clarity and impact of a true perception but without the external stimulation of the relevant sensory organ”<sup>2</sup> (cf. <sup>3-5</sup>), though this belies the difficulty in discerning the boundaries between normal and abnormal perception.<sup>6</sup> Hallucinations need to be distinguished from illusions, which are perceptual experiences in which an external stimulus is misperceived or misinterpreted.<sup>2</sup> In practice, hallucinations vary in content (eg, perception of people, animals, or objects), character (eg, frequency, emotional valence, location), duration (from seconds to chronically present), complexity (eg, perception of simple stimuli vs organized scenes or objects), and quality (eg, perceived reality, intrusiveness) and occur in all sensory modalities. The terms used to refer to hallucinations are equally diverse (see [table 1](#)).

Hallucinations occur in people with sensory, neurological, medical, neurodegenerative, and psychological disorders<sup>7</sup> as well as in those with no mental disorder at all.<sup>8-10</sup> In healthy (nonclinical) samples, hallucination prevalence (across modalities) is lower in older than younger adults.<sup>8,9</sup> In contrast, hallucinations are common in many clinical disorders associated with older age, with specific prevalence rates varying by condition, stage of illness, and symptom type. For example, visual hallucinations are common in dementia, Parkinson's disease, and in eye or visual pathway disease,<sup>11</sup> while auditory hallucinations are prevalent with hearing loss.<sup>12</sup> Similarly, multimodal visual, tactile, and

**Table 1.** Key Terms and Definitions of Hallucinations

| Type of Hallucination                     | Related Terms   | Definition   |
|---|---|--|
| Bereavement hallucinations                | <ul style="list-style-type: none"> <li>➤ Grief hallucinations</li> <li>➤ Sensed presence</li> <li>➤ Experience of continued presence</li> <li>➤ Guardian angel experience</li> </ul>  | The experience of seeing, hearing, feeling, tasting, smelling, and/or sensing the presence of the deceased.  |
| Charles Bonnet syndrome                   | <ul style="list-style-type: none"> <li>➤ “Phantom vision” syndrome</li> </ul>   | Typically involves the experience of complex (ie, formed) visual hallucinations, in the context of visual loss, with insight that the experience is not real, in people with no marked cognitive dysfunction.  |
| Complex hallucinations                    |   | The involuntary perception of an object or scene in the absence of a corresponding object/scene in the environment (ie, a formed perception whereby individual features have been linked or grouped into organized/connected wholes).  |
| Hallucinations                            | <ul style="list-style-type: none"> <li>➤ Private perceptions</li> <li>➤ Hearing voices (in the case of auditory hallucinations)</li> <li>➤ Seeing visions (in the case of visual hallucinations)</li> <li>➤ Unusual sensory experiences</li> <li>➤ Anomalous perceptions</li> </ul> | <p>“A sensory experience which occurs in the absence of corresponding external stimulation of the relevant sensory organ; has a sufficient sense of reality to resemble a veridical perception, over which the subject does not feel s/he has direct voluntary control and which occurs in the awake state.”<sup>3</sup></p> <p>“an erroneous percept in the absence of identifiable stimuli.”<sup>4</sup></p> <p>“[Perceiving] something involuntarily which, by all other measures, is not there.”<sup>5</sup></p> |
| Hypnagogic and hypnopompic hallucinations | <ul style="list-style-type: none"> <li>➤ Sleep-related hallucinations</li> </ul>  | Vivid, dreamlike experiences that occur on the borders of sleep. These anomalous perceptions can occur when falling asleep (hypnagogic) or waking up (hypnopompic).  |
| Multimodal hallucinations                 | <ul style="list-style-type: none"> <li>➤ Compound hallucinations</li> <li>➤ Polymodal hallucinations</li> <li>➤ Polysensual hallucinations</li> <li>➤ Intersensorial hallucinations</li> </ul>  | Hallucinations that occur in more than one modality simultaneously, typically emanating from a single source. NB. Sometimes refers to hallucinations in different sensory modalities experienced serially.   |
| Musical hallucinations                    | <ul style="list-style-type: none"> <li>➤ Musical hallucinosis</li> <li>➤ Musical ear syndrome</li> <li>➤ Auditory Charles Bonnet syndrome</li> <li>➤ Oliver Sack’s syndrome</li> </ul>  | The subjective experience of hearing music, or aspects of music, when none is being played. The perception of music can occur with or without voice and lyrics.  |
| Olfactory hallucinations                  | <ul style="list-style-type: none"> <li>➤ Phantasmia</li> <li>➤ Phantom smells</li> </ul>  | The detection of smells, when the corresponding odor is not present in the environment.  |
| Passage hallucinations                    | <ul style="list-style-type: none"> <li>➤ Sometimes referred to as “minor hallucinations”</li> </ul>   | The experience of a stimulus moving past the perceiver, in the periphery.  |
| Presence hallucinations                   | <ul style="list-style-type: none"> <li>➤ Feeling of presence</li> <li>➤ Sensed presence</li> </ul>  | The vivid sensation of the presence of another person or agent, usually close by, or just behind, the perceiver.   |
| Simple hallucinations                     |   | The perception of unformed stimuli (eg, colored lines, high-pitched tones), when there are no such stimuli in the environment (ie, perceptions involving specific stimulus features rather than whole objects).  |
| Tactile hallucinations                    | <ul style="list-style-type: none"> <li>➤ Hallucinations of touch</li> </ul>   | The perception of a tactile stimulus that is not explained by the actions of another person or external object   |
| Tinnitus                                  | <ul style="list-style-type: none"> <li>➤ Often called “ringing in the ears”</li> </ul>  | The perception of noises in one or both ears or inside the head, when no external sound source is present. Sounds often involve ringing, hissing, whistling, or buzzing but can be more complex (eg, a familiar tune).   |

auditory hallucinations tend to be more prominent in late- (between 40 and 60 years age) or very-late onset (60+ years) compared with early-onset schizophrenia.<sup>13</sup> Across conditions, both similarities and differences have been reported,<sup>14,15</sup> suggesting that the same assessments and treatments may not be appropriate for all presentations of hallucinations in older adults, which may be linked to the diversity of risk factors involved.<sup>16–19</sup>

Whilst our understanding, assessment, and treatment of hallucinations in older adults have improved in the last decade, greater priority needs to be given to

communicating these advances to clinicians so that clinical care can be grounded in the best available evidence. The International Consortium of Hallucinations Research Working Group on Hallucinations in Older Adults was set up to respond to this challenge. Accordingly, the purpose of this review is to highlight the key issues for the workforce caring for older adults with hallucinations; critically review current assessment tools, management guidelines, and treatment approaches for this population; and offer recommendations and resources to support best practice.

## Workforce Competencies and Training Issues

As familiar and trusted advisors, primary care physicians can play a critical role in the early phases of assessment and treatment of hallucinations in older adults by: debunking myths and stereotypes (eg, that everyone who hallucinates has a psychotic disorder), providing relevant facts about hallucinations (eg, that distress associated with hallucinations can be treated), liaising with the client's primary and specialist care network, and arranging referral (eg, when trauma or bereavement are central factors in distressing hallucinations). However, hallucinations are also reported in general hospital admissions,<sup>20,21</sup> emergency departments,<sup>22</sup> routine health-care appointments, and by residents in long-term care.<sup>23</sup> Consequently, staff in *all* these settings need up-to-date knowledge and skills to offer optimal care and support that fits the client's needs.

### *Client-Centered Factors*

Both complex and simple hallucinations can be a cause of considerable disruption to daily life (eg, aggressive behavior, falls, social withdrawal) and distress. For example, tinnitus—the experience of a persistent sound in the absence of an external source—can provoke anxiety, loneliness, and anger.<sup>24</sup> Similarly, hallucinations associated with postoperative delirium can be highly distressing and may contribute to the development of post-traumatic stress disorder.<sup>25</sup> These negative responses can be exacerbated by unhelpful interactions with the treating team (eg, when clinicians convey a lack of hope). Similarly, people with dementia and Parkinson's disease may show an initial phase of uncertainty and distress when hallucinations first begin, which abates when patients learn that the experiences are not real.<sup>26</sup> It is important to recognize, however, that hallucinations are relatively common in “healthy” older adults (ie, in the absence of psychotic disorder or dementia<sup>8,16</sup>) and are not necessarily distressing. For example, in Charles Bonnet syndrome, a variety of positive emotional responses (amusement, curiosity) have been reported.<sup>27</sup> That said, the role of emotions in hallucinations is often complex. For instance, older people who are lonely may be fearful that the treatment team will “take them away from them”—depriving them of the sense of social connection that hallucinations sometimes provide. Similarly, bereavement hallucinations, which are a common reaction after a loss, are not only often regarded as positive,<sup>17,28,29</sup> but are also associated with higher levels of depression, anxiety, and clinically impairing grief.<sup>17,30</sup>

Culture also has a significant influence on the meaning, content, and expression of hallucinations—as well as with beliefs about treatment.<sup>31,32</sup> Voice-hearing experiences tend to be viewed as more negative and threatening in high-income countries and more benign in low- or

middle-income countries.<sup>33</sup> Consequently, official guidelines and training programs now include cultural diversity as part of competency-based curricula,<sup>34</sup> and developing culturally safe practice is considered particularly important when working with indigenous people, First Nations, Native peoples, or Aboriginal and Torres Strait Islander communities in Australia.<sup>35</sup>

Negative stereotypes about hallucinations can hinder the disclosure of these experiences, leading to delays in accessing help.<sup>26,36</sup> For instance, hallucinations are often considered synonymous with psychotic disorder, which is frequently stereotyped in terms of dangerousness and incompetence. As a result, older adults with hallucinations are often concerned that they are becoming mentally ill or developing dementia and worry about how treating clinicians will respond.<sup>37</sup> Concerns about social disapproval can also lead to the same perceptual experience being described quite differently in different contexts.<sup>38</sup> As a general point, adopting the terminology that older adults use when describing their experiences can often help the clinician to gain a better insight into their client's understanding of hallucinations.

### *Practitioner-Centered Factors*

Low levels of knowledge about aging and hallucinations remain an ongoing issue amongst many professionals.<sup>39</sup> For example, some ophthalmologists and general practitioners remain unfamiliar with visual hallucinations arising from eye disease (ie, Charles Bonnet syndrome)—and consequently rarely discuss the possibility of hallucinatory experiences in patients with visual loss.<sup>27,37,40</sup> Similarly, auditory hallucinations are common in people with hearing impairment, which suggests that clinicians should enquire about hallucinations in hearing-impaired patients and assess hearing ability in older people with recent-onset auditory hallucinations.<sup>12</sup>

Biased thinking about hallucinations can also occur, despite the good intentions of staff to help their clients/patients. For example, fear that people with hallucinations might be dangerous may lead to less willingness to discuss voice-hearing experiences with patients.<sup>41</sup> In general, negative stereotypes have been shown to be associated with less focus on the patient (than the disease), lower endorsement of recovery as an outcome of care, and fewer referrals for specialist treatment<sup>42</sup> (see also reference<sup>43</sup>). Consequently, a growing number of programs are being trialed that promote stigma reduction and supportive, nonjudgmental attitudes toward hallucinations in healthcare professionals and students<sup>44</sup> (see [table 2](#)).

Finally, it is important for clinicians to think about the needs of the caregivers as well as the patient. For example, informal caregivers can find managing visual hallucinations in Parkinson's challenging, which can have a negative impact on their quality of life.<sup>26</sup> Consequently, the focus of “treatment” sometimes must shift from

the person experiencing hallucinations to providing psychoeducation (eg, about causes of hallucinations) and support (eg, coping methods) for the person who cares for them.

### Assessment Tools

For the purposes of this review, clinicians and researchers with particular expertise in hallucinations in older populations were asked to provide a list of key elements that underpin high-quality assessment tools as well as features specifically relevant to tools for assessing hallucinations in older adults (step 1). Thereafter, these same experts were asked to provide a list of existing assessment tools for hallucinations that may be used with older adults and describe their strengths and limitations (step 2). Finally, these assessment tools were summarized and compared with the elements from step 1.

#### *Criteria for Assessment Tools*

A list of the key elements that underpin high-quality assessment tools is presented in [table 3](#)<sup>45,46</sup> whereby general issues are presented first, followed by psychometric, structural, and practical issues that are specific to the assessment of hallucinations and to the context of assessing older adults in particular.

#### *Summary of Existing Assessment Tools for Hallucinations*

[Table 4](#) presents a selection of commonly used assessment tools for hallucinations, along with a brief summary of their psychometric properties, and their strengths and limitations. Of note, the majority of these measures were not developed specifically for older adults—so that their design was not necessarily based on the needs of older adults or any specific characteristics of hallucinations in older age groups.

In [table 4](#), it can be seen that, compared with self-report measures, there are relatively few clinician-administered tools regularly used with older adults. One of these (Assessment of Phantasmia) is for a very specific type of hallucination (ie, only for olfactory hallucinations), although it has been used in older populations<sup>67</sup> (cf. <sup>68</sup>). Another tool, the Auditory Hallucinations Rating Scale<sup>62,63</sup> is quite brief and assesses just auditory hallucinations, but is not widely used (for transcranial magnetic stimulation studies only). The North East Visual Hallucinations Inventory<sup>64-66</sup> has good psychometric properties and was developed with older populations in mind but assesses only visual hallucinations. The final two interview tools—the Psychotic Symptom Rating Scales (PSYRATS)<sup>60</sup> and the Questionnaire for Psychotic Experiences (QPE)<sup>69</sup>—are quite similar, in that both are detailed in the number of dimensions they assess, although the QPE offers a more complete assessment of

hallucinations modalities and delusions, whereas the PSYRATS assesses delusions but only auditory hallucinations.<sup>61</sup> Important to note is that the PSYRATS was developed for the assessment of patients with psychotic disorder, so it is arguably less suitable for older clinical groups where, eg, visual (and other) hallucinations dominate. However, the PSYRATS does show sensitivity to change and is, therefore, widely used in evaluating the treatment of hallucinations (cf. <sup>70-73</sup>). Although the PSYRATS has been in use for two decades, to the best of our knowledge, it has not been systematically investigated in older populations. Finally, it is still unknown if hallucination measures are invariant across samples, making comparisons of scores between different samples (eg, older adults and people with psychosis) invalid.

In terms of self-report measures, many of these assess hallucinations in a number of different modalities (eg, Cardiff Anomalous Perceptions Scale, CAPS<sup>53-55</sup>; Multi-Modality Unusual Sensory Experiences Questionnaire, MUSEQ<sup>59</sup>; Launay-Slade Hallucinations Scale, LSHS<sup>47</sup>; Extended LSHS<sup>48-50</sup>), and others are less comprehensive (eg, Community Assessment of Psychic Experiences, CAPE,<sup>51,52</sup> and Current CAPE-15).<sup>58</sup> Some measures were designed to assess hallucinatory experiences in older populations with a particular disorder—such as Parkinson's disease, eg, Psychosis and Hallucination Questionnaire<sup>56,57</sup>—whilst others were not specifically created for assessing hallucinations in a particular disorder (CAPS and E-LSHS) but have recently been used in the clinical studies of older populations, eg, the E-LSHS has been used in people with Alzheimer's and older nonclinical populations.<sup>74-76</sup> However, as with clinician-administered tools, very little research has directly compared the use of these self-report measures across age groups, ie, younger vs older adults (but see<sup>8,77</sup>) and/or diagnostic groups (ie, clinical vs nonclinical), and it, therefore, remains largely unknown whether these tools are sample invariant. This is important to consider, because if older adults are shown to be using existing tools differently to younger adults, then changes may need to be made to these tools to accommodate for this; in turn, this will help to ensure that these experiences can be assessed, and validly compared, across different groups.

Overall, clinician-administered interviews are often already in a suitable and convenient format for older adults—difficulty reading due to visual loss/impairment, items can be repeated for those with hearing loss—though clinicians sometimes lack confidence in talking about hallucinations, so formal training is required to learn how to approach this topic and to administer items in a standardized way. For example, the QPE,<sup>69</sup> which was developed with input from patient associations in several countries, provides 50 fully structured questions about hallucinations and is scripted to be low in stigma. However, interviews can be time-consuming, which may be a problem for adults with cognitive or motivational difficulties. To

**Table 2.** Recommendations for Training and Practice

| Training and Practice Points  | Examples   |
|---|--|
| <p>➤ <i>Training should sensitize future professionals to the complex nature of hallucinations in psychotic and nonpsychotic disorders and raise awareness that hallucinations can, and do, occur in the absence of a diagnosis of mental illness or a need for care.</i></p> | <p>Training should aim to:</p> <ol style="list-style-type: none"> <li>1) Provide knowledge about the multifactorial nature of hallucinations—individual features of the experience are complex (they can vary in content, emotional valence, frequency, duration, reality, location, distress, control, etc).</li> <li>2) Increase understanding that hallucinations have multiple causal risk factors. Though not an exhaustive list, this includes: physical (eg, sensory loss/impairment, intoxication, drug abuse/withdrawal, inflammation), psychological (eg, trauma, bereavement, impaired cognition, disrupted sleep), and social (eg, loneliness and social isolation, discrimination) factors.</li> <li>3) Challenge myths and stereotypes, eg, that hallucinations occur <i>only</i> in people with psychotic disorders, indicate a propensity to violence, or are untreatable. Know the facts: hallucinations occur not only in people with different diagnoses but also in the healthy population and often respond to treatment.</li> <li>4) Challenge beliefs about the need for care—hallucinations are sometimes viewed as helpful and positive, are not always associated with distress or disruption to daily life, and may <i>not</i> need an intervention.</li> </ol> |
| <p>➤ <i>Affirming, non-judgmental attitudes and behavior may encourage self-reporting and alleviate distress arising from hallucinations in older adults</i></p>  | <p>The following approaches may be helpful:</p> <ol style="list-style-type: none"> <li>1) Avoid trivializing or invalidating the patients’ experience and how it makes them feel.</li> <li>2) Ask the patient what their hallucinatory experience is like: everyone’s experience is different. What (if anything) bothers them most? Communicate your understanding of what they have said back to them, to check you have understood them correctly.</li> <li>3) Be patient, listen carefully, imagine being the person experiencing hallucinations—put yourself in their shoes.</li> <li>4) Ask the patient if there are things that do or do not help them cope with their hallucinations.</li> </ol>   |
| <p>➤ <i>When enquiring about the experience of hallucinations with older adults and their families/carers use non-stigmatizing language and provide accurate information about the help that is available.</i></p>  | <p>Non-stigmatizing ways of asking about hallucinations include:<br/>         “People sometimes hear another person speak, while there is no one there. Also, music or other sounds can be heard, while it is unclear where this comes from. In the past 7 days, have you ever heard such voices, music, or other sounds?”<br/>         “Over the past 7 days, have you seen things or images when there was no clear explanation for them? Or when no one else could see them? For example, people, animals, shadows, specific patterns, or objects?”<br/>         “People sometimes smell the scent of smoke, when there is no fire. Another example is someone who smells flowers, while there are no flowers around. Have you ever had this experience in the past 7 days?”<br/>         “People sometimes say they experience hearing and seeing things that others cannot see or hear both at the same time. Or they feel something/someone touching them they can also see, while others do not. If you feel comfortable, could you tell something about your experiences on this?”</p>   |

conclude, there is a clear need for an increased interest in hallucinations in older adults, both in terms of research in general and in terms of clinical practice (eg, the development and validation of optimal hallucination assessment tools for older adults and the existence of formal clinical training related to hallucinations in older adults). We encourage those working in a clinical setting to use the information presented here to choose the optimal hallucination assessment tools for their working context. These assessment issues are as important in a clinical setting as they are in research. Also, we recommend that clinicians

strive to further adapt, refine, and validate these tools to reduce the gap in evidence-based assessment tools available for older adults.

**Management and Treatment Approaches**

Current guidelines and treatment recommendations are largely based on expert consensus. The focus is typically on the overall management of a specific clinical condition, with hallucinations one of the symptoms covered, eg, NICE Guidelines for Parkinson’s disease.<sup>78</sup> To date,

**Table 3.** Quality Criteria for Assessment Tools

| General: Applies to All Measurement Tools   |  |
|---|--|
| <i>Possesses good psychometric properties<sup>a</sup></i>   | Content validity, internal consistency, construct validity, criterion validity, test-retest reliability, responsiveness (ie, ability to detect clinically important changes over time), floor and ceiling effects, cross-cultural validity, and interpretability (ie, the degree to which one can assign qualitative meaning to quantitative scores).  |
| <i>Clear and relevant instructions</i>  | State time period(s), ask participants to answer all the items, tell participants to exclude certain experiences or contexts (eg, “please do not include experiences where alcohol, cannabis, ecstasy, or other similar substances has been taken”), explain the response scale (eg, for 5-point response scales, inform participants to use the entire scale and not just the extreme points), and include “unsure/do not know” response possibility. |
| <i>Items should be clear and understandable</i>   | eg, use a clear typeface and legible font size.  |
| Specific: Applies to Measurement Tools for Hallucinations and in Older Populations                      |  |
| <i>Evidence that it is appropriate and feasible for use with older adults</i>                           | eg, adequate tool when used specifically with older adults, including those with sensory and cognitive limitations, or physical ill-health.  |
| <i>Psychometric properties are robust when used with older populations</i>                              | eg, factor invariance between older and younger adults reported, items cover all possible types/modalities of hallucinations (content validity), test-retest reliability reported (to help clinicians calculating reliable change indices), and evidence of sensitivity to change the following treatment.   |
| <i>Captures hallucination-related experiences</i>   | eg, illusions, misperceptions, intrusive thoughts, flashbacks, daydreaming, etc. and able to distinguish these from hallucinations.  |
| <i>Assessment beyond presence/absence of hallucinations</i>   | eg, frequency, variation, location, associated other factors (eg, lighting, presence of other people, etc.), consistent or variable (is there temporal consistency?), and impact of the experiences on the person (practical, emotional, etc.)   |
| <i>Inclusion of additional dimensions associated with the experience</i>                                | eg, whether or not the experience is associated with a certain degree of distress, conviction, preoccupation, etc.   |
| <i>Inclusion of (a) precise timeframe(s)</i>  | Specific timeframes (eg, “Have you had this experience in the past year?”) and/or lifetime timeframes (eg, “Have you <i>ever</i> had this experience?”). Further, time periods assessed must be able to capture the new or recent onset of hallucinations vs hallucinations experienced throughout life.   |
| <i>Question addressing whether or not the individual has talked about the experience(s) with others</i> | eg, “Have you discussed these experiences with your partner, carer, or doctor?”  |
| <i>Different versions of the measure available</i>  | Versions for: self, informant, clinician.  |
| <i>Question about the interpretability of the items</i>   | Whether or not the items were clear to the participant (and if not, which one(s) were unclear/difficult).  |
| <i>Inclusion of a brief screener</i>  | To identify people for whom a more detailed assessment may be warranted.   |
| <i>Introductory text states that the experiences have been shown to be quite common</i>                 | However, this needs to be done carefully, so that these experiences are not further stigmatized.   |
| <i>Assessment beyond hallucinations</i>   | eg, hearing, vision, health, cognition, medication (and any other variables that may be considered causally related to the hallucinatory experience in question), to help distinguish between age-related sensory change and perceptual anomalies.   |

<sup>a</sup>Based on Mokkink et al.<sup>45</sup> and Terwee et al.<sup>46</sup>

few guidelines have focused on hallucinations specifically (eg, <sup>79</sup>) and the forthcoming SHAPED (Study of Hallucinations in Parkinson’s disease, Eye disease, and Dementia) consensus guidelines will be the first to focus on visual hallucinations in older adults.

All guidelines for hallucinations take the view that different treatments for hallucinations are required at different disease or hallucination stages and that

experiencing hallucinations may not, in itself, require a specific treatment beyond general measures (eg, education, reassurance, physical, and medication review). For example, the SHAPED guidelines suggest including a review of cognitive and ophthalmological health, given that these may be masked by other conditions: ie, cognitive impairment may be missed in a patient with eye disease with their decline in functional ability attributed to visual

**Table 4.** Selected Examples of Assessment Tools for Hallucinations

| Measure  | Brief Description   | Psychometric Properties in Older Adults  | Strengths/Limitations   |
|--|---|--|---|
| Self-report questionnaires   |   |  |   |
| Launay-Slade Hallucinations Scale (LSHS). <sup>47</sup>  | Designed to assess hallucination predisposition in the general community. Original version has 12 items (Launay and Slade <sup>47</sup> ); an extended version has 16 items. <sup>48</sup> Items rated on a 5-point Likert scale: “0 = certainly does not apply to me,” “1 = possibly does not apply to me,” “2 = unsure,” “3 = possibly applies to me,” and “4 = certainly applies to me.” | The E-LSHS has good validity and internal reliability (Cronbach’s $\alpha = .87$ ). <sup>49,50</sup> Factor analyses of the E-LSHS indicate a 4-factor solution measuring: (a) auditory and visual HLEs, (b) multisensory HLEs, (c) intrusive thoughts, and (d) vivid daydreams. Psychometric data in older adults are currently being examined. For the 3 LSHS auditory hallucinations items, Cronbach’s $\alpha = .869$ in adults 60+ yrs (data derived from reference <sup>8</sup> ). | E-LSHS assesses a broad range of hallucinations in different modalities, including auditory, visual and olfactory, and items on hypnagogic and hypnopompic hallucinations and on sensed presence hallucinations.  |
| Community Assessment of Psychic Experiences (CAPE). <sup>51</sup>  | 42-item measure—designed to assess lifetime psychotic-like experiences in the general population. It contains 3 subscales assessing positive, negative psychotic symptoms, and depressive symptoms and also includes ratings of distress.   | Good validity and reliability, especially in younger samples. However, positive and negative subscales may be less reliable in older adults. <sup>52</sup>   | Provides comprehensive information about lifetime psychotic experiences. Available in 8 languages (from: <a href="http://cape42.homestead.com/index.html">http://cape42.homestead.com/index.html</a> ) Quite long.  |
| Cardiff Anomalous Perceptions Scale (CAPS). <sup>53,54</sup>   | 32-item measure—designed to assess anomalous perceptual experiences in the general community and clinical groups. Items scored YES or NO. If YES, items then rated for distress, intrusiveness, and frequency on a 5-point Likert scale.  | Good validity in nonclinical (18–54 yrs) and clinical (psychotic disorder) groups (25–64 yrs). Good internal reliability (Cronbach $\alpha = .87$ ) and test-retest reliability over 6 months (CAPS Total $r = .77$ ). Total scores uncorrelated with age. <sup>53</sup> Psychometric properties in older adults (50 yrs and above) currently being examined.  | Uses neutral, everyday language. Designed to assess anomalous perceptual experiences, rather than general aspects of psychosis-like experiences. Validated in Spanish. <sup>55</sup> Freely available: <a href="https://osf.io/fm34z/">https://osf.io/fm34z/</a> Quite long.  |
| Psychosis and Hallucinations Questionnaire (PsychHQ). <sup>56</sup> Informant version available. <sup>57</sup> | 20-item measure—designed to assess hallucinations and other psychotic symptoms, attention, and sleep disturbance in Parkinson’s Disease (PD). Frequency is rated on a 5-point Likert scale: Never, < 1 time per week, Weekly, Most days a week, Daily. Distress is rated on a 4-point Likert scale: None, Mild, Moderate, and Severe.   | Good validity, good test-retest (intra-class correlation = 0.9), and internal reliability (Cronbach $\alpha = 0.9$ ) in older patients with idiopathic PD. <sup>56</sup> (Note: average age of patients with positive response on PsychHQ $70.5 \pm 8.5$ yrs). Scores on Section I (core hallucinatory and psychotic symptoms) uncorrelated with age, disease duration, motor severity, or daily Levodopa equivalent dose.   | Brief, typically < 10 mins. Developed in consultation with patients, caregivers, and clinicians and uses layman language. Questionnaire available from the authors upon request. Probes a broad spectrum of visual and nonvisual hallucinatory phenomena. Can help pick up PD hallucinations that may otherwise go missed by clinicians. Utility for assessing hallucinations in other disorders unclear. |
| Current Community Assessment of Psychic Experiences-15 (Current CAPE-15). <sup>58</sup>                        | 15-item version of the CAPE-42 measures positive “psychotic-like” experiences that have occurred in the last 3 months. Contains 3 subscales measuring persecutory ideation, bizarre experiences, and perceptual abnormalities, including ratings of distress.   | Good validity and internal reliability in younger adults (Cronbach’s $\alpha = .79$ ). <sup>58</sup> Psychometric properties in older adults not evaluated.  | Provides information about recent hallucinatory and psychotic-like experiences. Shortened version of the original 42-item CAPE questionnaire. Questionnaire freely available. <sup>58</sup>   |

Table 4. Continued

| Measure   | Brief Description  | Psychometric Properties in Older Adults   | Strengths/Limitations  |
|---|--|---|--|
| Multi-Modality Unusual Sensory Experiences Questionnaire (MUSEQ). <sup>59</sup> | 43-items assess unusual sensory experiences in 6 modalities: auditory, visual, olfactory, gustatory, bodily sensations, and sensed presence. Items rated on a 5-point Likert scale: 0 = Never, 1 = Hardly Ever, 2 = Rarely, 3 = Occasionally, and 4 = Frequently.  | Acceptable test-retest reliability ( $r = .56-0.77$ ) and good internal reliability (Cronbach $\alpha = .77-88$ ), and good construct and discriminant validity in nonclinical (mean = 27.75 and range 17-76 yrs) and clinical groups, including schizophrenia spectrum disorder and bipolar disorder (mean = 34.17 and range 18-67 yrs.). Psychometric properties in older adults not evaluated. | Provides information about sensory experiences in a number of modalities. Items designed to assess unusual sensory experiences according to a continuum structure (ie, most frequent to least frequent phenomena). Open access. <sup>59</sup> Quite long.  |
| Clinician Administered  |  |   |  |
| Psychotic Symptom Rating Scales (PSYRATS). <sup>60</sup>                        | Structured interview for auditory hallucinations (and delusions) in patients with psychotic disorders. Symptoms in the last week are rated: 0 = no problem, 1 = minimal or occasional, 2 = minor to moderate, 3 = major, and 4 = maximum severity. Auditory hallucinations are also evaluated on frequency, duration, location, loudness, beliefs regarding origin of voices, negativity, distress, disruption, and controllability. | Good inter-rater and test-retest reliability, and good validity. Factor analysis shows a 4-factor solution measuring Distress, Frequency, Attribution, and Loudness. <sup>61</sup>  | Provides a comprehensive, multidimensional assessment of auditory hallucinations. German, French, Indonesian, Malay, Portuguese, and Chinese translations available.   |
| Auditory Hallucinations Rating Scale (AHRs). <sup>62,63</sup>                   | Brief (7-items), structured clinical interview that measures the frequency, reality, loudness, number of voices, length, attentional salience, and distress of auditory hallucinations.  | Adequate inter-rater and test-retest reliability and moderate internal consistency (Cronbach's $\alpha = .60$ ). <sup>62</sup> Psychometric properties in older adults not explored.  | Provides a shorter alternative to the PSYRATS. Not widely used.  |
| North East Visual Hallucinations Inventory (NEVHI). <sup>64</sup>               | Semi-structured interview designed to assess hallucinations in older adults with eye disease and cognitive impairment. Qualitative items rated on a 3-point Likert scale: 0 = never, 1 = sometimes, and 2 = always.  | Good validity and good inter-rater and internal reliability (Cronbach $\alpha = .71$ ). <sup>65</sup> Good convergent and divergent validity in older adults with PD (mean age $68.9 \pm 7.6$ yrs). <sup>66</sup>   | Includes brief screening questions. Examines both simple and complex visual hallucinations. Explores social, emotional, and behavioral impact of hallucinations. Brief administration time. Captures qualitative features of phantom smells. Some people may not fully understand the meaning of Phantosmia. Responses may be subject to bias. |
| Assessment of Phantosmia. <sup>67</sup>   | Single-item measure ("Have you in the last year experienced the so-called phantom smells?") scored 0 = "Never" to 4 = "Always." When present, fixed follow-up questions enquire about the type, intensity, duration, frequency, recency, and chronology of the experience.   | Psychometric properties not formally assessed. However, phantosmia was <i>not</i> correlated with olfactory dysfunction, supporting the discriminant validity of objective and subjective olfactory measures. Prevalence of phantosmia reported to be uncorrelated with age in healthy individuals (60-90 yrs).   | Brief administration time. Captures qualitative features of phantom smells. Some people may not fully understand the meaning of Phantosmia. Responses may be subject to bias.  |
| Assessment of Phantosmia. <sup>68</sup>   | Standardized assessment with a single, negatively valenced item "Do you sometimes smell an unpleasant, bad, or burning odor when nothing is there?" Responses coded: Yes/No.   | Psychometric properties not reported. For adults 40 yrs and above, an age-related decline in unpleasant, bad, or burning phantosmia observed for women but not men.   | Assessment limited to olfactory modality. Positive or neutral phantom smells are not assessed. No information on intensity, duration, or periodicity.  |



Table 4. Continued

| Measure  | Brief Description  | Psychometric Properties in Older Adults  | Strengths/Limitations   |
|--|--|--|---|
| Questionnaire for Psychotic Experiences (QPE). <sup>69</sup> | 50-item QPE designed to assess the presence, severity, and phenomenology of hallucinations (and delusions) across diagnostic groups. | Good validity and good test-retest reliability, inter-rater reliability, and internal consistency in patients with schizophrenia, schizoaffective disorder, bipolar disorder, and major depressive disorder and nonclinical participants (mean age: 40.3, 43.4, 32.1, 30.2, and 28.6 yrs, respectively). Psychometric properties in older adults/ other diagnoses currently under examination. | Designed for use across a range of disorders. Available from: <a href="http://www.qpeinterview.com/en">www.qpeinterview.com/en</a> Quite long: 20-40mins administration time (but high completion rate, see reference <sup>69</sup> ). Requires training No specific comparisons of QPE between older and younger adults. |

loss. Early provision of information about the risk of hallucinations is emphasized as a way of reducing stigma and for healthcare professionals to routinely ask about hallucinations—to shift the onus of reporting hallucinations away from the patient. The point at which specific pharmacological or non-pharmacological interventions for hallucinations are required is not clearly defined in guidelines but based on clinical judgment.

*Differential Diagnosis*

Before commencing treatment, it must be clear that hallucinations are causing distress, ie, that there is a need for treatment. If this is the case, the second point of attention is whether it is indeed hallucinations. Especially in older adults with cognitive dysfunction, it can be difficult to disentangle hallucinations from obsessions, misperceptions/ misunderstandings (ie, illusions), or involuntary mental imagery, such as the so-called "earworms" (ie, songs in the mind that continually repeat).<sup>80</sup>

*Purpose of Treatment*

For some disorders, such as intoxication, psychotic depression, and schizophrenia, hallucinations may respond well to treatment of the underlying disorder. However, in other disorders, such as dementia, vision or hearing loss, or Parkinson's disease, this is not the case. In such instances, additional treatment aimed specifically at hallucinations may be indicated. For the treatment of hallucinations, the most important question is what the aim of treatment should be. There are a number of answers frequently given to this question:

1. I want to understand why I experience these hallucinations.
2. I want to be competent to handle these hallucinations.
3. I want to get rid of these hallucinations.

*For Purpose 1: Psychoeducation.* If the response to this question is in line with answer 1, then psychoeducation is

the treatment of choice. In one or more sessions, the patient and his/her loved one can be provided with information about how perception is accomplished in the brain, how this process can go awry, and which factors can precipitate hallucinations. A good start for psychoeducation is to ask the patient what he/she already knows and which explanation he/she currently uses for this experience. From there, unhelpful explanations can be corrected and new knowledge can be added to improve disease insight.

*For Purpose 2: Psychological Therapy.* If the answer is close to the description under point 2, then psychological therapy that helps the person to develop effective (and avoid ineffective) strategies and skills for coping with hallucinations, and any distress associated with these experiences, is recommended. Cognitive behavioral therapies help clients think and feel differently about hallucinations. Improving coping skills can also help to reduce distress, which may contribute to the onset or maintenance of hallucinations.<sup>81</sup> In the case of bereavement hallucinations, it is important to take a relational psychotherapeutic perspective on the experience, as the distress may signify relationship difficulties with the deceased, eg unfinished business and intrusive presence.<sup>82,83</sup> Several psychotherapies initially developed for treating people with a primary psychotic disorder and auditory hallucinations (cognitive behavioral therapy, COMET, acceptance, and commitment) are also applied to older persons,<sup>84,85</sup> though less is known about the application of cognitive behavioral therapy for distressing visual hallucinations.<sup>86</sup> In some cases, adjustments need to be made when the cognitive resources of patients are limited. The essence of such therapies is that the patient learns that hallucinations are not a real-life threat, may have personal significance or meaning, or can safely be ignored. If (auditory) hallucinations have neutral content, then psychotherapy developed for tinnitus may be a better fit, as it focuses on the reduction of worry, and shifting attention away from the unwanted perceptions.<sup>87</sup>

*For Purpose 3: The Following Steps Can Be Used. Step 1: Check Medication* Checking medication records is important since several types of medication can induce

hallucinations, especially those with anticholinergic activity and those that increase monoaminergic function. People with cognitive dysfunction are at particular risk for such side effects. The most commonly used hallucination-triggering medication are corticosteroids, levetiracetam (an anti-epileptic drug), anti-malaria medication, dopaminergic agonists (pramipexole, rotigotine, ropinirole, etc.), losartan (an antihypertensive drug), and opioids such as tramadol. If there is a correlation in time between the onset of hallucinations and start of medication use, it may be worthwhile to taper off that medicine or replace it by another one and reevaluate hallucination severity.

*Step 2: Risk Factor Management* Risk factors for hallucinations include physical health, environmental, psychological, and social factors. Any obvious triggers to the hallucinations should be identified. Comorbid physical health factors increase the risk of hallucinations, including visual and hearing impairment and physical illnesses (eg, some metabolic and endocrine disorders, and psychiatric disorders such as depression and psychotic disorders). Optimize sensory modes by using glasses, perhaps cataract operation is an option, use hearing aids. Good sleep hygiene is key, with darkness in nighttime and bright lights (preferably sunlight) at day. In terms of environment, it is key to provide well-lit rooms, without dark corners. Reduce background noise as much as possible, especially during conversations. At the social level, good company is an excellent prevention for hallucinations and may reduce their frequency and intensity.

*Step 3: Pharmacotherapy* If the patient wants to reduce hallucinations and previous strategies were not successful, pharmacotherapy can be an effective means to do so, although side effects may be severe, especially in older people. It is important to discuss the unstable course of hallucinations and the possibility that they will disappear spontaneously. Considering that hallucinations can arise from aberrations in many neurotransmitters systems, including the dopaminergic, serotonergic, glutamatergic, and cholinergic system, then specific medication may be effective only in specific subtypes. The phenomenology of the hallucinations may provide some clues to the direction of which receptor system may be involved.<sup>88</sup> For example, dopamine couples salience to experiences and increased dopamine production can lead to highly salient, often frightening hallucinations, as seen in people with psychotic depression, schizophrenia, delirium, and post-traumatic stress disorder. Antipsychotic medication can be effective for this specific type of hallucinations.<sup>89–91</sup> As dopamine receptors decrease with age, much lower dosages are used for older adults; hence, the adage “start low, go slow” to titrate until the lowest effective dose is achieved. Sedative antipsychotics need to be given at nighttime to reduce the risk of falls. Electrocardiogram

for potential QT elongation should be performed before and after the start of risperidone, aripiprazole, and typical antipsychotics.<sup>92</sup> As antipsychotic use has been associated with significant mortality and morbidity risks for older patients, especially those with dementia, such medication should be avoided if possible and tapered off if not effective or when hallucinations have been in stable remission when it is used.<sup>91,93</sup>

Hallucinations, especially in the visual domain, in older adults can also arise from the loss of cholinergic innervation, especially in people with neurodegenerative disorders, such as Alzheimer’s, Huntington’s, or Parkinson’s disease. As acetylcholine is an important neurotransmitter in sustained attention, patients with loss of cholinergic innervation often show drowsiness, inattention, and forgetfulness (“what was the reason I went to the kitchen?”). Cholinesterase inhibitors such as donepezil, rivastigmine, and galantamine can be effective in treating this type of hallucination.<sup>94,95</sup> If using rivastigmine, patches may be better tolerated than pills as they provide fewer gastrointestinal side effects.<sup>96,97</sup> Starting dose is usually 4.6 mg/24 hours, which is increased to 9 mg/24 hours after 3–5 weeks if generally tolerated, although side effects are also common.<sup>98</sup>

*Step 4: Physical Therapy* In older individuals, pharmacotherapy often induces side effects. Further, antipsychotic medication use in the elderly has been associated with increased mortality.<sup>91,93</sup> Hence, an alternative treatment may be to use electrical or magnetic therapies. Electroconvulsive therapy (ECT) is not only the best-known option but also the most intensive one. ECT may be an excellent option for older adults with psychotic depression as it is rapid and highly effective for both the depressive and the psychotic symptoms. Cognitive side effects can occur but are generally not lasting and may be ameliorated by the use of cholinesterase inhibitors during the ECT course.<sup>99</sup> For other types of hallucinations in older adults, ECT is seldom used. Transcranial magnetic stimulation and transcranial direct (or alternating) current stimulation have been mostly applied for auditory verbal hallucinations,<sup>100,101</sup> but could also be an option for tactile hallucinations.<sup>102,103</sup>

## Summary and Directions for Future Research

Hallucinations are common in older adults. The character of these experiences is varied and for many, though not all, they can cause significant distress. Understanding the diverse origins, nature, and reactions to hallucinations is vital in helping clinicians to provide the best level of care (see Resources). There is currently no consensus on the most suitable tool(s) for assessing hallucinations in older individuals, with or without a co-occurring clinical disorder. A range of valid and reliable measures is available for the screening and assessment of hallucinations, though

these were largely not designed specifically for older age groups. Variation in the scope and content of these measures means that: (1) the phenomenological features, emotional reactions, and impact on the life of hallucinations in older patients may be incompletely captured and (2) differences in the experience of hallucinations across age groups or diagnostic categories may be missed. Clinicians also need to maintain awareness of potential barriers to disclosure of hallucinations and the value of gaining information from multiple sources (self, informant, and clinician) when discussing these experiences with older clients. Similarly, although treatment and management approaches are slowly being tailored to the needs, views, and context of older age groups, considerably more effort is needed in studying how to provide a personalized response to older clients with hallucinations and those who care for them.<sup>88</sup> Finally, future research would benefit from a more detailed investigation of the profile of similarities and differences in hallucinations across clinical disorders and age groups to facilitate differential diagnosis, and the detection of early features (“red flags”) warranting a referral to more specialized services.

## Resources

- *British Tinnitus Association* <https://www.tinnitus.org.uk/>—Provides links to professional events, decision tools, and resources for healthcare professionals
- *BMJ Parkinson's Disease: Summary of updated NICE guidelines* <https://www.bmj.com/content/358/bmj.j1951>
- *Charles Bonnet Syndrome Foundation* <http://www.charlesbonnetsyndrome.org/>—Provides links to resources, research articles, and professionals' toolkit.
- *Esme's umbrella* <http://www.charlesbonnetsyndrome.org/>—Education and information resource for Charles Bonnet syndrome.
- Perth Voices Clinic <https://perthvoicesclinic.com.au/resources-for-clinicians/>—Resources for clinicians working with people with all forms of hallucinations
- RNIB sight loss advice <https://www.rnib.org.uk/eye-health/eye-conditions/charles-bonnet-syndrome-cbs>—Education and information resource for Charles Bonnet syndrome.
- Royal College of Psychiatrists / MindEd for families [https://mindedforfamilies.org.uk/Content/other\\_people\\_tell\\_me\\_i\\_am\\_seeing\\_things](https://mindedforfamilies.org.uk/Content/other_people_tell_me_i_am_seeing_things)—Education and information resource older adults experiencing visual hallucinations.
- Tinnitus Australia <https://tinnitusaustralia.org.au>—Provides information, guidance, and updates to help people manage their tinnitus.

## Funding

D.H.F.F., J.O., J.-P.T., and D.C. were supported by the National Institute for Health Research (NIHR)

Programme Grants for Applied Research Grant (RP-PG-0610-10100-SHAPED).

## Acknowledgments

The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. Sommer, Collerton, and Larøi are co-developers of scales included in table 4. There are no other conflicts of interest in relation to the subject of this study.

## References

1. United Nations. *World Population Prospects: the 2019 revision*. 2019. [https://population.un.org/wpp/Publications/Files/WPP2019\\_Highlights.pdf](https://population.un.org/wpp/Publications/Files/WPP2019_Highlights.pdf). Accessed October 11, 2019.
2. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders: DSM 5*. Washington, DC: American Psychiatric Pub Incorporated; 2013.
3. David AS. The cognitive neuropsychiatry of auditory verbal hallucinations: an overview. *Cogn Neuropsychiatry*. 2004;9(1-2):107–123.
4. Majjer K, Hayward M, Fernyhough C, et al. Hallucinations in children and adolescents: an updated review and practical recommendations for clinicians. *Schizophr Bull*. 2019;45(Suppl 1):S5–S23.
5. Collerton D, Taylor JP, Tsuda I, et al. How can we see things that are not there? Current insights into complex visual hallucinations. *J Conscious Stud*. 2016;23(7–8):195–227.
6. Blom JD. Defining and measuring hallucinations and their consequences — what is really the difference between a veridical perception and a hallucination? Categories of hallucinatory experience. In: Collerton D, Mosimann UP, Perry E, eds. *The Neuroscience of Visual Hallucinations*. Chichester: Wiley; 2014:23–45.
7. Waters F, Blom JD, Jardri R, Hugdahl K, Sommer IEC. Auditory hallucinations, not necessarily a hallmark of psychotic disorder. *Psychol Med*. 2018;48(4):529–536.
8. Larøi F, Bless JJ, Laloyaux J, et al. An epidemiological study on the prevalence of hallucinations in a general-population sample: effects of age and sensory modality. *Psychiatry Res*. 2019;272:707–714.
9. Majjer K, Begemann MJH, Palmén SJMC, Leucht S, Sommer IEC. Auditory hallucinations across the lifespan: a systematic review and meta-analysis. *Psychol Med*. 2018;48(6):879–888.
10. Kelsall-Foreman I, Bucks RS, Weinborn M, Gavett B, Badcock JC. An examination of the nature of hallucinations and other anomalous perceptual experiences in healthy community-dwelling older adults. *Psychol Assess*. (under revision).
11. O'Brien J, Taylor J, Ballard C, et al. Visual hallucinations in neurological and ophthalmological disease: pathophysiology and management. *J Neurol Neurosurg Psychiatry*. 2020;91(5):512–519.
12. Linszen MMJ, van Zanten GA, Teunisse RJ, Brouwer RM, Scheltens P, Sommer IE. Auditory hallucinations in adults with hearing impairment: a large prevalence study. *Psychol Med*. 2019;49(1):132–139.
13. Cort E, Meehan J, Reeves S, Howard R. Very late-onset schizophrenia-like psychosis: a clinical update. *J Psychosoc Nurs Ment Health Serv*. 2018;56(1):37–47.

14. Dudley R, Aynsworth C, Mosimann U, et al. A comparison of visual hallucinations across disorders. *Psychiatry Res.* 2019;272:86–92.
15. Dauwan M, Linszen MMJ, Lemstra AW, Scheltens P, Stam CJ, Sommer IE. EEG-based neurophysiological indicators of hallucinations in Alzheimer's disease: comparison with dementia with Lewy bodies. *Neurobiol Aging.* 2018;67:75–83.
16. Badcock JC, Dehon H, Larøi F. Hallucinations in healthy older adults: an overview of the literature and perspectives for future research. *Front Psychol.* 2017;8:1134.
17. Kamp KS, O'Connor M, Spindler H, Moskowitz A. Bereavement hallucinations after the loss of a spouse: associations with psychopathological measures, personality and coping style. *Death Stud.* 2019;43(4):260–269.
18. Hugdahl K, Sommer IE. Auditory verbal hallucinations in schizophrenia from a levels of explanation perspective. *Schizophr Bull.* 2018;44(2):234–241.
19. ffytche DH, Pinto R, Krzyzanowski H, et al. Visual hallucinations in dementia: preliminary findings from the Study of Hallucinations in Parkinson's disease, Eye disease and Dementia (SHAPED). *Alzheimers Dement.* 2017;13(7):P1461–P1462.
20. Goldberg SE, Whittamore KH, Harwood RH, Bradshaw LE, Gladman JR, Jones RG; Medical Crises in Older People Study Group. The prevalence of mental health problems among older adults admitted as an emergency to a general hospital. *Age Ageing.* 2012;41(1):80–86.
21. Wade DM, Brewin CR, Howell DC, White E, Mythen MG, Weinman JA. Intrusive memories of hallucinations and delusions in traumatized intensive care patients: an interview study. *Br J Health Psychol.* 2015;20(3):613–631.
22. Waters F, Dragovic M. Hallucinations as a presenting complaint in emergency departments: prevalence, diagnosis, and costs. *Psychiatry Res.* 2018;261:220–224.
23. Helvik AS, Selbæk G, Šaltyté Benth J, Røen I, Bergh S. The course of neuropsychiatric symptoms in nursing home residents from admission to 30-month follow-up. *PLoS One.* 2018;13(10):e0206147.
24. Marks E, Smith P, McKenna L. Living with tinnitus and the health care journey: an interpretative phenomenological analysis. *Br J Health Psychol.* 2019;24(2):250–264.
25. Drews T, Franck M, Radtke FM, et al. Postoperative delirium is an independent risk factor for posttraumatic stress disorder in the elderly patient: a prospective observational study. *Eur J Anaesthesiol.* 2015;32(3):147–151.
26. Renouf S, ffytche D, Pinto R, Murray J, Lawrence V. Visual hallucinations in dementia and Parkinson's disease: a qualitative exploration of patient and caregiver experiences. *Int J Geriatr Psychiatry.* 2018;33(10):1327–1334.
27. Cox TM, ffytche DH. Negative outcome Charles Bonnet syndrome. *Br J Ophthalmol.* 2014;98(9):1236–1239.
28. Castelnovo A, Cavallotti S, Gambini O, D'Agostino A. Post-bereavement hallucinatory experiences: a critical overview of population and clinical studies. *J Affect Disord.* 2015;186:266–274.
29. Rees WD. The hallucinations of widowhood. *BMJ.* 1971;4(5778):37–41.
30. Lee SA. The persistent complex bereavement inventory: a measure based on the DSM-5. *Death Stud.* 2015;39(7):399–410.
31. Larøi F, Luhrmann TM, Bell V, et al. Culture and hallucinations: overview and future directions. *Schizophr Bull.* 2014;40 (Suppl 4):S213–S220.
32. Badcock JC, Clark M, Morgan VA. Hallucinations in indigenous and non-indigenous Australians: findings from the second Australian national survey of psychosis. *Schizophr Res.* 2018;197:581–582.
33. Luhrmann TM, Padmavati R, Tharoor H, Osei A. Differences in voice-hearing experiences of people with psychosis in the U.S.A., India and Ghana: interview-based study. *Br J Psychiatry.* 2015;206(1):41–44.
34. Jarvis GE, Lyer S, Andermann L, Fung F. Culture and psychosis in clinical practice. In: Badcock JC, Paulik G eds. *A Clinical Introduction to Psychosis: Foundations for Clinical Psychologists and Neuropsychologists.* Cambridge, MA: Academic Press; 2019.
35. Parker R, Milroy H. Mental illness in Aboriginal and Torres Strait Islander peoples. In: Dudgeon P, Milroy H, Walker R, eds. *Working Together: Aboriginal and Torres Strait Islander Mental Health and Wellbeing Principles and Practice.* Canberra, Australia: Commonwealth of Australia, 2014:113–124.
36. Vilhauer RP. Stigma and need for care in individuals who hear voices. *Int J Soc Psychiatry.* 2017;63(1):5–13.
37. Pang L. Hallucinations experienced by visually impaired: Charles Bonnet syndrome. *Optom Vis Sci.* 2016;93(12):1466–1478.
38. Bennett G, Bennett KM. The presence of the dead: an empirical study. *Mortality* 2000;5(2):139–157.
39. Bennett S, Ilderton P, O'Brien JT, Taylor JP, Teodorczuk A. Teaching provision for old age psychiatry in medical schools in the UK and Ireland: a survey. *BJPsych Bull.* 2017;41(5):287–293.
40. Gordon KD, Felfeli T. Family physician awareness of Charles Bonnet syndrome. *Fam Pract.* 2018;35(5):595–598.
41. White MR, Stein-Parbury J, Orr F, Dawson A. Working with consumers who hear voices: the experience of early career nurses in mental health services in Australia. *Int J Ment Health Nurs.* 2019;28(2):605–615.
42. Corrigan PW, Druss BG, Perlick DA. The impact of mental illness stigma on seeking and participating in mental health care. *Psychol Sci Public Interest.* 2014;15(2):37–70.
43. McFerran D, Hoare DJ, Carr S, Ray J, Stockdale D. Tinnitus services in the United Kingdom: a survey of patient experiences. *BMC Health Serv Res.* 2018;18(1):110.
44. Orr F. *I know how it feels: a voice-hearing simulation to enhance nursing students' empathy and self-efficacy* [dissertation]. Sydney, Australia: Faculty of Health, University of Technology, Sydney; 2017.
45. Mookink LB, Terwee CB, Patrick DL, et al. The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study. *Qual Life Res.* 2010;19(4):539–549.
46. Terwee CB, Bot SD, de Boer MR, et al. Quality criteria were proposed for measurement properties of health status questionnaires. *J Clin Epidemiol.* 2007;60(1):34–42.
47. Launay G, Slade P. The measurement of hallucinatory predisposition in male and female prisoners. *Pers Individ Dif.* 1981;2(3):221–234.
48. Larøi F, Van Der Linden M. Nonclinical participants' reports of hallucinatory experiences. *Can J Behav Sci.* 2005;37(1):33–43.
49. Siddi S, Ochoa S, Laroi F, et al. A cross-national investigation of hallucination-like experiences in 10 countries:

- the E-CLECTIC study. *Schizophr Bull.* 2019;45(45 Suppl 1):S43–S55.
50. Vellante M, Larøi F, Cella M, Raballo A, Petretto DR, Preti A. Hallucination-like experiences in the nonclinical population. *J Nerv Ment Dis.* 2012;200(4):310–315.
  51. Stefanis NC, Hanssen M, Smirnis NK, et al. Evidence that three dimensions of psychosis have a distribution in the general population. *Psychol Med.* 2002;32(2):347–358.
  52. Mark W, Touloupoulou T. Psychometric properties of “community assessment of psychic experiences”: review and meta-analyses. *Schizophr Bull.* 2016;42(1):34–44.
  53. Bell V, Halligan PW, Ellis HD. The Cardiff Anomalous Perceptions Scale (CAPS): a new validated measure of anomalous perceptual experience. *Schizophr Bull.* 2006;32(2):366–377.
  54. Bell V, Halligan PW, Pugh K, Freeman D. Correlates of perceptual distortions in clinical and non-clinical populations using the Cardiff Anomalous Perceptions Scale (CAPS): associations with anxiety and depression and a re-validation using a representative population sample. *Psychiatry Res.* 2011;189(3):451–457.
  55. Tamayo-Agudelo W, Jaén-Moreno MJ, León-Campos MO, Holguín-Lew J, Luque-Luque R, Bell V. Validation of the Spanish-language Cardiff Anomalous Perception Scale. *PLoS One.* 2019;14(3):e0213425.
  56. Shine JM, Mills JMZ, Qiu J, et al. Validation of the psychosis and hallucinations questionnaire in non-demented patients with Parkinson’s disease. *Mov Disord Clin Pract.* 2015;2(2):175–181.
  57. Muller AJ, Mills JMZ, O’Callaghan C, et al. Informant- and self-appraisals on the Psychosis and Hallucinations Questionnaire (PsychH-Q) enhances detection of visual hallucinations in Parkinson’s disease. *Mov Disord Clin Pract.* 2018;5(6):607–613.
  58. Capra C, Kavanagh DJ, Hides L, Scott JG. Current CAPE-15: a measure of recent psychotic-like experiences and associated distress. *Early Interv Psychiatry.* 2017;11(5):411–417.
  59. Mitchell CAA, Maybery MT, Russell-Smith SN, Collerton D, Gignac GE, Waters F. The structure and measurement of unusual sensory experiences in different modalities: the Multi-Modality Unusual Sensory Experiences Questionnaire (MUSEQ). *Front Psychol.* 2017;8(1363):1–17.
  60. Haddock G, McCarron J, Tarrier N, Faragher EB. Scales to measure dimensions of hallucinations and delusions: the Psychotic Symptom Rating Scales (PSYRATS). *Psychol Med.* 1999;29(4):879–889.
  61. Woodward TS, Jung K, Hwang H, et al. Symptom dimensions of the psychotic symptom rating scales in psychosis: a multisite study. *Schizophr Bull.* 2014;40 (Suppl 4):S265–S274.
  62. Hoffman RE, Gueorguieva R, Hawkins KA, et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. *Biol Psychiatry.* 2005;58(2):97–104.
  63. Hoffman RE, Hawkins KA, Gueorguieva R, et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication-resistant auditory hallucinations. *Arch Gen Psychiatry.* 2003;60(1):49–56.
  64. Mosimann UP, Collerton D, Dudley R, et al. A semi-structured interview to assess visual hallucinations in older people. *Int J Geriatr Psychiatry.* 2008;23(7):712–718.
  65. Aynsworth C, Collerton D, Dudley R. Measures of visual hallucinations: review and recommendations. *Clin Psychol Rev.* 2017;57:164–182.
  66. Holiday KA, Pirogovsky-Turk E, Malcarne VL, et al. Psychometric properties and characteristics of the north-east visual hallucinations interview in Parkinson’s disease. *Mov Disord Clin Pract.* 2017;4(5):717–723.
  67. Sjölund S, Larsson M, Olofsson JK, Seubert J, Laukka EJ. Phantom smells: prevalence and correlates in a population-based sample of older adults. *Chem Senses.* 2017;42(4):309–318.
  68. Bainbridge KE, Byrd-Clark D, Leopold D. Factors associated with phantom odor perception among US adults: findings from the national health and nutrition examination survey. *JAMA Otolaryngol Head Neck Surg.* 2018;144(9):807–814.
  69. Rossell SL, Schutte MJL, Toh WL, et al. The questionnaire for psychotic experiences: an examination of the validity and reliability. *Schizophr Bull.* 2019;45(45 Suppl 1):S78–S87.
  70. Wykes T, Hayward P, Thomas N, et al. What are the effects of group cognitive behaviour therapy for voices? A randomised control trial. *Schizophr Res.* 2005;77(2-3):201–210.
  71. Drake R, Haddock G, Tarrier N, Bentall R, Lewis S. The Psychotic Symptom Rating Scales (PSYRATS): their usefulness and properties in first episode psychosis. *Schizophr Res.* 2007;89(1-3):119–122.
  72. Moritz S, Kerstan A, Veckenstedt R, et al. Further evidence for the efficacy of a metacognitive group training in schizophrenia. *Behav Res Ther.* 2011;49(3):151–157.
  73. Craig TK, Rus-Calafell M, Ward T, et al. AVATAR therapy for auditory verbal hallucinations in people with psychosis: a single-blind, randomised controlled trial. *Lancet Psychiatry.* 2018;5(1):31–40.
  74. El Haj M, Jardri R, Larøi F, Antoine P. Hallucinations, loneliness, and social isolation in Alzheimer’s disease. *Cogn Neuropsychiatry.* 2016;21(1):1–13.
  75. ElHajM, GalloujK, DehonH, RocheJ, LarøiF. Hallucinations in Alzheimer’s disease: failure to suppress irrelevant memories. *Cogn Neuropsychiatry.* 2018;23(3):142–153.
  76. El Haj M, Badcock JC, Jardri R, et al. A look into hallucinations: the relationship between visual imagery and hallucinations in Alzheimer’s disease. *Cogn Neuropsychiatry.* 2019;24(4):275–283.
  77. Larøi F, DeFruyt F, van Os J, Aleman A, Van der Linden M. Associations between hallucinations and personality structure in a non-clinical sample: comparison between young and elderly samples. *Pers Individ Dif.* 2005;39(1):189–200.
  78. NICE. *Parkinson’s disease in adults. Report No.: NG71 2017.* <https://www.parkinsons.org.uk/professionals/resources/nice-guideline-ng71-parkinsons-disease-adults>. Accessed October 11, 2019.
  79. ffytche DH. Visual hallucination and illusion disorders: a clinical guide. *Adv Clin Neurosci Rehabil.* 2004;4(2):16–18.
  80. Sommer IE, Selten JP, Diederer KM, Blom JD. Dissecting auditory verbal hallucinations into two components: audibility (Gedankenlautwerden) and alienation (thought insertion). *Psychopathology* 2010;43(2):137–140.
  81. Paulik G, Hayward M, Jones AM, Badcock JC. Evaluating the “C” and “B” in brief cognitive behaviour therapy for distressing voices in routine clinical practice in an uncontrolled study. *Clin Psychol Psychother.* 2019;26:734–742.
  82. Hayes J, Leudar I. Experiences of continued presence: on the practical consequences of ‘hallucinations’ in bereavement. *Psychol Psychother.* 2016;89(2):194–210.
  83. Hayes J, Steffen EM. Working with welcome and unwelcome presence in grief. In: Klass D, Steffen EM, eds. *Continuing Bonds in Bereavement: New Directions for Research and Practice.* New York, NY: Routledge; 2018.

84. van der Gaag M, van Oosterhout B, Daalman K, Sommer IE, Korrelboom K. Initial evaluation of the effects of Competitive Memory Training (COMET) on depression in schizophrenia-spectrum patients with persistent auditory verbal hallucinations: a randomized controlled trial. *Br J Clin Psychol*. 2012;51(2):158–171.
85. Badcock JC, Paulik G, eds. *A Clinical Introduction to Psychosis: Foundations for Clinical Psychologists and Neuropsychologists*. Cambridge, MA: Academic Press (an imprint of Elsevier); 2019.
86. Thomson C, Wilson R, Collerton D, Freeston M, Dudley R. Cognitive behavioural therapy for visual hallucinations: an investigation using a single-case experimental design. *Cogn Behav Ther*. 2017;10:e10.
87. Thompson DM, Hall DA, Walker DM, Hoare DJ. Psychological therapy for people with tinnitus: a scoping review of treatment components. *Ear Hear*. 2017;38(2):149–158.
88. Sommer IE, Kleijer H, Hugdahl K. Toward personalized treatment of hallucinations. *Curr Opin Psychiatry*. 2018;31(3):237–245.
89. Bloomfield K, MacDonald L, Finucane G, Snow B, Roxburgh R. Use of antipsychotic medications in patients with Parkinson's disease at Auckland City Hospital. *Intern Med J*. 2012;42(7):e151–e156.
90. Goetz CG, Fan W, Leurgans S. Antipsychotic medication treatment for mild hallucinations in Parkinson's disease: positive impact on long-term worsening. *Mov Disord*. 2008;23(11):1541–1545.
91. Chiesa D, Marengoni A, Nobili A, et al.; REPOSI Investigators. Antipsychotic prescription and mortality in hospitalized older persons. *Psychogeriatrics* 2017;17(6):397–405.
92. Madhusoodanan S, Shah P, Brenner R, Gupta S. Pharmacological treatment of the psychosis of Alzheimer's disease: what is the best approach? *CNS Drugs*. 2007;21(2):101–115.
93. Koponen M, Taipale H, Lavikainen P, et al. Risk of mortality associated with antipsychotic monotherapy and polypharmacy among community-dwelling persons with Alzheimer's disease. *J Alzheimers Dis*. 2017;56(1):107–118.
94. Li DD, Zhang YH, Zhang W, Zhao P. Meta-analysis of randomized controlled trials on the efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease. *Front Neurosci*. 2019;13:472.
95. Matsunaga S, Fujishiro H, Takechi H. Efficacy and safety of cholinesterase inhibitors for mild cognitive impairment: a systematic review and meta-analysis. *J Alzheimers Dis*. 2019;71(2):513–523.
96. Farlow MR, Somogyi M. Transdermal patches for the treatment of neurologic conditions in elderly patients: a review. *Prim Care Companion CNS Disord*. 2011;13(6):PCC.11r01149.
97. Sadowsky C, Perez JA, Bouchard RW, Goodman I, Tekin S. Switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch. *CNS Neurosci Ther*. 2010;16(1):51–60.
98. Reñé R, Ricart J, Hernández B; researchers in the Experience study. From high doses of oral rivastigmine to transdermal rivastigmine patches: user experience and satisfaction among caregivers of patients with mild to moderate Alzheimer disease. *Neurologia*. 2014;29(2):86–93.
99. Stryker R, Ophir D, Bar F, Spivak B, Weizman A, Strous RD. Rivastigmine treatment for the prevention of electroconvulsive therapy-induced memory deficits in patients with schizophrenia. *Clin Neuropharmacol*. 2012;35(4):161–164.
100. Slotema CW, Aleman A, Daskalakis ZJ, Sommer IE. Meta-analysis of repetitive transcranial magnetic stimulation in the treatment of auditory verbal hallucinations: update and effects after one month. *Schizophr Res*. 2012;142(1-3):40–45.
101. Koops S, van den Brink H, Sommer IE. Transcranial direct current stimulation as a treatment for auditory hallucinations. *Front Psychol*. 2015;6:244.
102. Koops S, Sommer IEC. Transcranial direct current stimulation (tDCS) as a treatment for visual hallucinations: a case study. *Psychiatry Res*. 2017;258:616–617.
103. Jardri R, Pins D, Thomas P. A case of fMRI-guided rTMS treatment of coenesthetic hallucinations. *Am J Psychiatry*. 2008;165(11):1490–1491.